Myelodysplastic syndrome classification

Ghariani, Ines; Braham, Najia; Hassine, Mohsen; Kortas, M.

doi:10.1684/abc.2013.0804

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various subtypes of MDS have a risk of transformation to acute myeloid leukemia (AML) (1,2). Recently, the chromosome aberrations in MDS have been elucidated; interstitial deletion of chromosome 5 is the most common cytogenetic abnormality in MDS (3).…”

Section: Introductionmentioning

confidence: 99%

“…Myelodysplastic syndrome (MDS) encompasses a diverse group of neoplastic bone marrow disorders, characterized by abnormal cellular morphology and defects in the normal differentiation and proliferation of hematopoietic precursors. Various subtypes of MDS have a risk of transformation to acute myeloid leukemia (AML) ( 1 , 2 ). Recently, the chromosome aberrations in MDS have been elucidated; interstitial deletion of chromosome 5 is the most common cytogenetic abnormality in MDS ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis

Nian

Xiao

Wang

et al. 2014

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Secreted protein acidic and rich in cysteine (SPARC) plays key roles in erythropoiesis; haploinsufficiency of SPARC is implicated in the progression of the 5q- syndrome. However, the role of SPARC in other subtypes of myelodysplastic syndrome (MDS) is not fully understood, particularly in the del(5q) type with a complex karyotype, which has a high risk to transform into acute myeloid leukemia (AML). In the present study, we investigated the role of SPARC in the proliferation and apoptosis of SKM-1 cells, an acute myeloid leukemia cell line transformed from an MDS cell line. SKM-1 cells were infected with SPARC-RNAi-LV or NC-GFP-LV lentivirus. Apoptosis and cell cycle profiling were assessed by flow cytometry, and cell proliferation was evaluated by MTS assay. The mRNA and protein expression levels of SPARC, p53, caspase-3, caspase-9 and Fas were detected by RT-PCR, real-time PCR and western blot assay. The SPARC shRNA constructed by us led to a significant reduction in SPARC expression in SKM-1 cells. SPARC knockdown inhibited the proliferation of SKM-1 cells by inducing cell cycle arrest at the G1/G0 phase and apoptosis. SPARC knockdown elevated the expression of p53, caspase-9, caspase-3 and Fas at both the mRNA and protein levels. SPARC silencing inhibited the growth of AML transformed from MDS by activating p53-induced apoptosis and cell cycle arrest. These data indicate that SPARC acts as an oncogene in transformed MDS/AML and is a potential therapeutic target in MDS/AML.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis

Nian

Xiao

Wang

et al. 2014

International Journal of Molecular Medicine

View full text Add to dashboard Cite

show abstract

“…(2) Exclude other hematopoietic and non-hematopoietic system diseases that can lead to reduced blood cells and pathological hematopoiesis. Determination criteria: (1) morbid hematopoiesis: bone marrow smear with at least 10% of any lines of red blood cell, neutrophil, or megakaryocyte; (2) the proportion of circular iron granulocytes occupying nuclear red blood cells is ≥15%; (3) primitive cells: 5%–19% in bone marrow smear; (4) chromosome abnormalities ( 19 , 20 ). The literature indicates that MDS has multiple gene mutations, and spontaneous self-remission in de novo MDS is very rare ( 21 , 22 ).…”

Section: Discussionmentioning

confidence: 99%

Myelodysplastic syndrome-like response after voriconazole treatment of systemic lupus erythematosus complicated with fungal infection: a case report

Xie,

Wang,

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundVoriconazole is mainly used to treat progressive and potentially life-threatening infections in immunocompromised patients. The adverse drug reactions related to voriconazole are varied. In some rare cases, the use of voriconazole can result in myelodysplastic syndrome (MDS)-like adverse reactions.Case presentationHere, we present a rare case of systemic lupus erythematosus patient with a fungal infection that developed MDS-like adverse reactions after treatment with voriconazole. The patient was admitted to the hospital because of 3 days of chest tightness and dyspnea. After the admission, the patient’s sputum culture showed Candida albicans infection, and voriconazole was prescribed to be taken orally. After using voriconazole, drug-related adverse reactions such as visual impairment, nausea, vomiting, hiccup, middle and lower abdominal pain, disorders of consciousness, delirium, hallucination, slow response, and subcutaneous ecchymosis appeared, as well as the gradually increased serum creatinine, oliguria, and aggravated lower limb edema. In addition, there was a decrease in peripheral blood cells, and MDS-like changes in bone marrow were indicated by bone marrow biopsy. After discontinuing voriconazole, drug-related adverse symptoms disappeared, and hematocytopenia and the changes in MDS were significantly improved, which was confirmed by a subsequent bone marrow puncture at a 6 months interval.ConclusionThis case reminded us that when using voriconazole for treatment, individual differences in patients should be considered, and the blood concentration of voriconazole should be closely monitored. Otherwise, potential drugs that affect voriconazole metabolism should be noted, and related adverse symptoms of patients should be closely observed during medication to reduce the occurrence of adverse drug events.

show abstract

“…Myelodysplastic syndromes (MDS) are a group of rare and malignant clonal stem cell disorders. These are classified as hematologic malignancies caused by ineffective hematopoiesis, resulting in morphologic dysplasia, bone marrow failure, and high-risk transformation to acute myeloid leukemia (AML) [ 1 ]. This typically arises secondary to a multistep genetic process in which mutations affecting DNA damage and cellular stress responses affect transcription, RNA splicing, epigenetics, and cytokine signaling, which, in turn, leads to the initiation and propagation of malignant clones [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Myelodysplastic Syndromes and Modalities of Treatment: An Updated Literature Review

Zamora¹,

Patel²,

Grossmann³

et al. 2021

Cureus

View full text Add to dashboard Cite

Myelodysplastic syndrome classification

Cited by 5 publications

References 0 publications

SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis

SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis

Myelodysplastic syndrome-like response after voriconazole treatment of systemic lupus erythematosus complicated with fungal infection: a case report

Myelodysplastic Syndromes and Modalities of Treatment: An Updated Literature Review

Contact Info

Product

Resources

About